Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC01585 is a long intergenic non-protein coding RNA gene located in the human genome and transcribed into a non-coding RNA longer than 200 nucleotides that does not overlap protein-coding regions[1][3][5]. It acts primarily as a modulator of gene expression and appears to inhibit breast cancer cell proliferation and growth when overexpressed[2]. Mechanistically, it binds the NONO nuclear protein; when LINC01585 is downregulated, NONO instead interacts with CRTC, promoting cAMP/CREB-mediated gene transcription and cancer cell growth[2]. LINC01585, like other lincRNAs, contributes to the fine-tuning of gene expression with remarkable tissue specificity and regulatory diversity[5][7]. It is being investigated as a potential biomarker in cancer but is not currently considered a receptor, enzyme, or known drug target.
Not applicable, as there are no drugs known to target LINC01585.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1585 (LINC01585).